Anavex (AVXL) Life Sciences announced that its board has appointed former senior VP of clinical development and current senior advisor Terrie Kellmeyer as interim CEO. The appointment follows the departure of president and CEO Christopher Missling from the company on April 30 and the board’s request for his resignation. Anavex said it expects to file a Form 12b-25 to extend the filing date of its Form 10-Q for the quarter ended March 31, as it does not expect to meet the SEC due date.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex Life Sciences Names Interim CEO Amid Leadership Shift
- AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls
- Anavex initiated with a Buy at Rodman & Renshaw
- Reaffirming Buy on Anavex: Long-Term Value in Blarcamesine Outweighs Near-Term Regulatory Setbacks
- Anavex gives update after blarcamesine marketing authorization withdrawal